← Back to Search

Cannabinoid

CBD for Social Anxiety Disorder

Q: Is there an ongoing opportunity to join this experiment?

<p>This research project, which was initially posted on November 30th 2023 and updated lastly on November 7th 2023 is not currently seeking potential study participants. Despite this particular trial being dormant, 459 other studies are actively recruiting patients.</p>

Phase < 1

Waitlist Available

Led By David Tolin, Ph.D.

Research Sponsored by Hartford Hospital

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Primary diagnosis of SAD according to the DIAMOND

At least moderate severity of SAD as evidenced by a DIAMOND severity rating of 4 (moderate) or higher

Timeline

Screening 3 weeks

Treatment Varies

Follow Up single session (2.5 hours)

Awards & highlights

Study Summary

This trial will look at how CBD affects fear levels in people with social anxiety disorder.

Who is the study for?

This trial is for adults over 18 with social anxiety disorder (SAD) of at least moderate severity. Participants must be able to understand English as the study materials are only in English. They should not be on medications that interact with cannabidiol (CBD).Check my eligibility

What is being tested?

The study tests if oral CBD can help reduce fear more effectively than a placebo during a process called fear extinction, which is part of therapy for SAD.See study design

What are the potential side effects?

Potential side effects from CBD may include tiredness, diarrhea, changes in appetite or weight, but specific side effects will be monitored throughout the trial.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Select...

I have been diagnosed with Social Anxiety Disorder.

Select...

My social anxiety is rated moderate or worse.

Select...

I am 18 years old or older.

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ single session (2.5 hours)

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~single session (2.5 hours)

This trial's timeline: 3 weeks for screening, Varies for treatment, and single session (2.5 hours) for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Distress ratings

Skin conductance

Trial Design

2Treatment groups

Experimental Treatment

Placebo Group

Group I: CannabidiolExperimental Treatment2 Interventions

600 mg oral cannabidiol

Group II: PlaceboPlacebo Group2 Interventions

Placebo capsules

0 / 3Eligibility criteria met

Find a Location

Who is running the clinical trial?

Hartford HospitalLead Sponsor

133 Previous Clinical Trials

18,912 Total Patients Enrolled

David Tolin, Ph.D.Principal InvestigatorHartford Hospital

1 Previous Clinical Trials

22 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Is there an ongoing opportunity to join this experiment?

"This research project, which was initially posted on November 30th 2023 and updated lastly on November 7th 2023 is not currently seeking potential study participants. Despite this particular trial being dormant, 459 other studies are actively recruiting patients."

Answered by AI